Abdeltawab Khaled, Yagan Jude, Megahed Mohammed, Zahab Mohamed A, Gheith Osama A, Rida Suzann, Nair Prasad, Mahmoud Tarek, Maher Ayman M, Al-Mohareb Sheikha, Mohamed Medhat, Al-Otaibi Torki
From the Nephrology Department, Hamed Al-Essa Organ Transplant Center, Sabah Area, Kuwait.
Exp Clin Transplant. 2019 Jan;17(Suppl 1):142-144. doi: 10.6002/ect.MESOT2018.P9.
Organ transplant in patients with congenital bleeding disorders is a challenge requiring an integrated approach of various specialists. Inherited factor VII deficiency is the most common of the rare bleeding disorders, with a wide set of hemorrhagic features. Although a kidney allograft is the most frequent type of solid-organ transplant, it is rarely performed in individuals with congenital hemorrhagic disorders. Here, we highlight the course of a patient with coagulation factor VII deficiency who underwent successful kidney transplant without significant coagulopathy. Our patient was a 19-year-old man with end-stage kidney disease and congenital coagulation factor VII deficiency. Perioperative bleeding was successfully prevented by administration of recombinant factor VII, confirming its safety in solid-organ transplants. Success requires evaluation of doses and therapeutic schedules, as well as a multidisciplinary approach.
